Wuxi apptec: postponement and change of fund use of some A-share IPO projects
Cailian news agency, Dec. 31, Wuxi apptec announced that the company considered and approved the proposal on the extension of some A-share initial raising investment projects and the change of fund use, which still needs to be submitted to the general meeting of shareholders of the company for deliberation. The company plans to change the implementation subject and location of the "Suzhou drug safety evaluation center expansion project", that is, the purpose of the raised funds will be changed to "Suzhou and Nantong drug safety evaluation center expansion project", and the time of scheduled availability will be extended.
This text is a result of machine translation.
Related companies：
In-depth
Jan 05, 2023 07:33 PM
Nov 16, 2022 05:19 PM
Nov 10, 2022 02:39 PM
Nov 08, 2022 08:32 AM
Briefing Jun 23, 2022 02:14 PM
· Financials
Minsheng Bank newly established the post of chief economist Wen bin
Briefing Jun 13, 2022 09:44 AM
· Healthcare
Cro plate fell, and Wuxi apptec fell nearly 10%
Healthcare
CRO ClinChoice Raises USD 150 Mn in Series E Round
2015 is the inflection point for the development of China's innovative drug industry and CRO (clinical research organization). On July 22nd, 2015, after CDE (Center For Drug Evaluation) released the announcement on self-examination and verification of drug clinical trial data, the supervision of Chinese clinical trials moved towards standardization. The investment and financing of innovative drugs in China continued to increase, laying the foundation for the growth of CRO.
Jul 05, 2022 08:17 PM
Briefing May 18, 2022 09:28 AM
· Technology
97 shares were financed to buy more than 100 million yuan, and BYD was the first to buy 1.113 billion yuan
Healthcare
Revenue and Net Profit of Wuxi Apptec Both Increased in 2020
Wuxi apptec said that the main reasons for the company's performance growth were the high growth of laboratories in China and the year-on-year growth of CDMO plate. China laboratory service is the core business of Wuxi apptec, accounting for more than 50% of its revenue. Its main business is small molecule drug discovery, drug analysis and testing.
Mar 31, 2021 11:38 AM
See more
Read next
Insight
In-depth